Literature DB >> 24914330

Role of microRNAs in gastric cancer.

Hideyuki Ishiguro1, Masahiro Kimura1, Hiromitsu Takeyama1.   

Abstract

Although gastric cancer (GC) is one of the leading causes of cancer-related death, major therapeutic advances have not been made, and patients with GC still face poor outcomes. The prognosis of GC also remains poor because the molecular mechanisms of GC progression are incompletely understood. MicroRNAs (miRNAs) are noncoding RNAs that are associated with gastric carcinogenesis. Studies investigating the regulation of gene expression by miRNAs have made considerable progress in recent years, and abnormalities in miRNA expression have been shown to be associated with the occurrence and progression of GC. miRNAs contribute to gastric carcinogenesis by altering the expression of oncogenes and tumor suppressors, affecting cell proliferation, apoptosis, motility, and invasion. Moreover, a number of miRNAs have been shown to be associated with tumor type, tumor stage, and patient survival and therefore may be developed as novel diagnostic or prognostic markers. In this review, we discuss the involvement of miRNAs in GC and the mechanisms through which they regulate gene expression and biological functions. Then, we review recent research on the involvement of miRNAs in GC prognosis, their potential use in chemotherapy, and their effects on Helicobacter pylori infections in GC. A greater understanding of the roles of miRNAs in gastric carcinogenesis could provide insights into the mechanisms of tumor development and could help to identify novel therapeutic targets.

Entities:  

Keywords:  Chemosensitivity; Circulating MicroRNA; Gastric cancer; Helicobacter pylori; MicroRNA; Reverse transcription-polymerase chain reaction

Mesh:

Substances:

Year:  2014        PMID: 24914330      PMCID: PMC4024779          DOI: 10.3748/wjg.v20.i19.5694

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  72 in total

Review 1.  Small non-coding RNAs as novel therapeutics.

Authors:  M Rossbach
Journal:  Curr Mol Med       Date:  2010-06       Impact factor: 2.222

2.  MicroRNA-155 is essential for the T cell-mediated control of Helicobacter pylori infection and for the induction of chronic Gastritis and Colitis.

Authors:  Mathias Oertli; Daniela B Engler; Esther Kohler; Manuel Koch; Thomas F Meyer; Anne Müller
Journal:  J Immunol       Date:  2011-08-31       Impact factor: 5.422

3.  Low-level expression of let-7a in gastric cancer and its involvement in tumorigenesis by targeting RAB40C.

Authors:  Qiaoyuan Yang; Zhigang Jie; Hong Cao; Anne R Greenlee; Chengfeng Yang; Fei Zou; Yiguo Jiang
Journal:  Carcinogenesis       Date:  2011-02-24       Impact factor: 4.944

4.  RAS is regulated by the let-7 microRNA family.

Authors:  Steven M Johnson; Helge Grosshans; Jaclyn Shingara; Mike Byrom; Rich Jarvis; Angie Cheng; Emmanuel Labourier; Kristy L Reinert; David Brown; Frank J Slack
Journal:  Cell       Date:  2005-03-11       Impact factor: 41.582

5.  Increased miR-222 in H. pylori-associated gastric cancer correlated with tumor progression by promoting cancer cell proliferation and targeting RECK.

Authors:  Na Li; Bin Tang; En-Dong Zhu; Bo-sheng Li; Yuan Zhuang; Shu Yu; Dong-shui Lu; Quan-Ming Zou; Bin Xiao; Xu-Hu Mao
Journal:  FEBS Lett       Date:  2012-02-02       Impact factor: 4.124

Review 6.  Methylation of tumor suppressor microRNAs: lessons from lymphoid malignancies.

Authors:  Lu Qian Wang; Raymond Liang; Chor Sang Chim
Journal:  Expert Rev Mol Diagn       Date:  2012-09       Impact factor: 5.225

7.  Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival.

Authors:  Junichi Takamizawa; Hiroyuki Konishi; Kiyoshi Yanagisawa; Shuta Tomida; Hirotaka Osada; Hideki Endoh; Tomoko Harano; Yasushi Yatabe; Masato Nagino; Yuji Nimura; Tetsuya Mitsudomi; Takashi Takahashi
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

8.  Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma.

Authors:  Laura Gramantieri; Manuela Ferracin; Francesca Fornari; Angelo Veronese; Silvia Sabbioni; Chang-Gong Liu; George A Calin; Catia Giovannini; Eros Ferrazzi; Gian Luca Grazi; Carlo M Croce; Luigi Bolondi; Massimo Negrini
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

9.  Posttranscriptional regulation of interleukin-10 expression by hsa-miR-106a.

Authors:  Amit Sharma; Manish Kumar; Jyotirmoi Aich; Manoj Hariharan; Samir K Brahmachari; Anurag Agrawal; Balaram Ghosh
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-23       Impact factor: 11.205

10.  Circulating miR-17-5p and miR-20a: molecular markers for gastric cancer.

Authors:  Mei Wang; Hongbing Gu; Sheng Wang; Hui Qian; Wei Zhu; Ling Zhang; Chonghui Zhao; Yang Tao; Wenrong Xu
Journal:  Mol Med Rep       Date:  2012-03-08       Impact factor: 2.952

View more
  38 in total

1.  Diagnostic significance of miR-106a in gastric cancer.

Authors:  Xu Hou; Miao Zhang; Haiquan Qiao
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  Prognostic role of microRNA-31 in various cancers: a meta-analysis.

Authors:  Shuwei Wang; Jun Hu; Dongsheng Zhang; Juan Li; Qiang Fei; Yueming Sun
Journal:  Tumour Biol       Date:  2014-08-20

3.  Overexpression of miR-218 inhibits hepatocellular carcinoma cell growth through RET.

Authors:  Chengjun Sui; Feng Xu; Weifeng Shen; Li Geng; Feng Xie; Binghua Dai; Jiongjiong Lu; Minfeng Zhang; Jiamei Yang
Journal:  Tumour Biol       Date:  2014-11-06

4.  Upregulation of microRNA-23a/b promotes tumor progression and confers poor prognosis in patients with gastric cancer.

Authors:  Gang Ma; Weijie Dai; Aiyu Sang; Xiaozhong Yang; Chengcheng Gao
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01

5.  Evaluation of Radiotherapy on miR-374 Gene Expression in Colorectal Cancer Patient Blood Samples.

Authors:  Azam Ahmadi; Mohammad Reza Bayatiani; Fatemeh Seif; Jamshid Ansari; Parisa Rashidi; Mona Moghadasi; Mobarakeh Etemadi
Journal:  Rep Biochem Mol Biol       Date:  2022-01

6.  Clinical role of miR-421 as a novel biomarker in diagnosis of gastric cancer patients: A meta-analysis.

Authors:  Yingying Xu; Guiping Wang; Wenqing Hu; Songbing He; Dandan Li; Ping Chen; Jinjie Zhang; Yongshun Gao; Duonan Yu; Liang Zong
Journal:  Medicine (Baltimore)       Date:  2022-05-13       Impact factor: 1.817

7.  miR-485-5p acts as a negative regulator in gastric cancer progression by targeting flotillin-1.

Authors:  Min Kang; Mei-Ping Ren; Lei Zhao; Chang-Ping Li; Ming-Ming Deng
Journal:  Am J Transl Res       Date:  2015-11-15       Impact factor: 4.060

8.  Concomitant Up-Regulation of Hsa- Mir-374 and Down-Regulation of Its Targets, GSK-3β and APC, in Tissue Samples of Colorectal Cancer.

Authors:  Mohammad Reza Bayatiani; Azam Ahmadi; Reza Aghabozorgi; Fatemeh Seif
Journal:  Rep Biochem Mol Biol       Date:  2021-01

9.  Emerging roles and mechanisms of microRNA‑222‑3p in human cancer (Review).

Authors:  Danhua Wang; Yiwen Sang; Tao Sun; Piaoping Kong; Lingyu Zhang; Yibei Dai; Ying Cao; Zhihua Tao; Weiwei Liu
Journal:  Int J Oncol       Date:  2021-03-24       Impact factor: 5.650

10.  MiR-17 and miR-93 Promote Tumor Progression by Targeting p21 in Patients with Chordoma.

Authors:  Wei Dong; Jingwu Li; Xiaoliu Dong; Wenjian Shi; Yu Zhang; Yongliang Liu
Journal:  Onco Targets Ther       Date:  2021-05-12       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.